APTOCROM Inc. Stock

A109960

KR7109960005

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 2026-07-30			5-day change	1st Jan Change
1,597.00 ^KRW	+0.13%		-2.44%	-68.06%

Jun. 30	Aprogen Biologics Inc. announced that it has received KRW 50.8 billion in funding from APTOCROM Inc.	CI
May. 25	Aprogen Biologics Inc. announced that it expects to receive KRW 50.8 billion in funding from APTOCROM Inc.	CI

Aptocrom Inc, formerly AP Healthcare Inc, is a Korea-based company primarily engaged in the pharmaceutical business. The Company operates its business through three segments. The Pharmaceutical Business segment is mainly engaged in the distribution and sale of drugs such as digestive organs medicine, outer skin medicine, nutrient tonic alteration and antibiotics. The Insulation Business segment is mainly engaged in the production, design, manufacturing and construction of industrial insulation. The Rental Business segment is mainly engaged in the real estate business such as offices and laboratories. The Company sells its products in domestic and overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-07-30	₩1,597.00	+0.13%	3,909
26-07-29	₩1,595.00	-0.19%	9,627
26-07-28	₩1,598.00	-1.78%	6,116
26-07-27	₩1,627.00	-0.97%	7,212
26-07-24	₩1,643.00	+1.17%	2,952

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Stock Market
Stocks
A109960 Stock

Stock markets for all

100% Free Registration

Market Cap	17.63B 12.34M 10.72M 9.95M 9.18M 17.29M 1.18B 17.6M 118M 46.14M 585M 46.34M 45.33M 1.97B	P/E 2024	-2.12x	P/E 2025	-9.5x
Enterprise Value	435M 304K 264K 246K 226K 427K 29.07M 434K 2.91M 1.14M 14.44M 1.14M 1.12M 48.55M	EV / Sales 2024	4.85x	EV / Sales 2025	3.87x
Free-Float	41.27%	Yield 2024 *	-	Yield 2025	-

Jun. 30	Aprogen Biologics Inc. announced that it has received KRW 50.8 billion in funding from APTOCROM Inc.	CI
May. 25	Aprogen Biologics Inc. announced that it expects to receive KRW 50.8 billion in funding from APTOCROM Inc.	CI
May. 14	APTOCROM Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 08	Aprogen Medicines Inc. announced that it has received KRW 12 billion in funding from APTOCROM Inc.	CI
May. 07	APTOCROM Inc. announced that it has received KRW 12.00000164 billion in funding from Nexkonics Inc.	CI
Apr. 27	Aprogen Medicines Inc. announced that it expects to receive KRW 12 billion in funding from APTOCROM Inc.	CI
Apr. 27	APTOCROM Inc. announced that it expects to receive KRW 12.00000164 billion in funding from Nexkonics Inc.	CI
Mar. 20	APTOCROM Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Mar. 15	APTOCROM Inc. announces Annual dividend	CI
Nov. 13	APTOCROM Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-13	APTOCROM Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-06-24	AP Healthcare Inc. announced that it has received KRW 10 billion in funding from Aprogen, Inc.	CI
25-05-21	Aprogen Medicines Inc. agreed to acquire an additional 20.06% stake in AP Healthcare Inc. from Aprogen Biologics Inc. for KRW 58.4 billion.	CI

1 day	+0.13%
1 week	-2.44%
Current month	-8.53%
1 month	-8.79%
3 months	-50.71%
6 months	-68.56%
Current year	-68.06%

1 week	1,430	1,671
1 month	1,430	1,790
Current year	1,430	5,400
1 year	1,430	11,820
3 years	1,430	49,900
5 years	1,430	113,000
10 years	1,430	426,000

Manager	Title	Age	Since
Jung-Chool Kim CEO	Chief Executive Officer	70	2022-03-22
Young-Suk Yeom AUD	Comptroller/Controller/Auditor	51	-
Jong-Su Kang SAM	Sales & Marketing	62	-

APTOCROM Inc. Stock

Stocks

A109960

KR7109960005

Pharmaceuticals

Valuation: APTOCROM Inc.

Chart: APTOCROM Inc.

Latest news : APTOCROM Inc.

Quotes and Performance

Course Extremes

Managers and Directors: APTOCROM Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Director	Title	Age	Since
Soon-Kyu Park BRD	Director/Board Member	59	-
Jung-Chool Kim BRD	Director/Board Member	70	2022-03-22
Jae-Seob Kim BRD	Director/Board Member	63	2017-01-09

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
APTOCROM INC.	+0.13%	-2.44%	-75.35%	-94.01%	12.13M
ELI LILLY AND COMPANY	-4.55%	-2.61%	+51.95%	+151.91%	1,079B
JOHNSON & JOHNSON	-3.66%	-1.33%	+52.95%	+46.62%	640B
ABBVIE INC.	-2.24%	+0.19%	+35.97%	+70.64%	465B
ROCHE HOLDING AG	-2.29%	+1.12%	+36.13%	+31.18%	353B
NOVARTIS AG	-2.28%	-0.69%	+33.42%	+40.48%	301B
ASTRAZENECA PLC	-3.15%	+0.25%	+10.63%	+15.03%	271B
NOVO NORDISK A/S	-2.12%	+3.31%	+1.82%	-37.38%	228B
AMGEN INC.	0.00%	+4.34%	+28.63%	+64.00%	209B
GILEAD SCIENCES, INC.	-1.09%	+0.32%	+14.40%	+70.80%	165B
Average	-1.64%	+4.07%	+19.05%	+35.93%	370.97B
Weighted average by Cap.	-1.62%	+4.86%	+38.04%	+72.89%

	2024	2025
Net sales	16.4B 11.48M 9.97M 9.26M 8.54M 16.09M 1.1B 16.38M 110M 42.93M 544M 43.11M 42.17M 1.83B	9.81B 6.87M 5.96M 5.54M 5.11M 9.62M 655M 9.79M 65.56M 25.67M 326M 25.78M 25.22M 1.09B
Net income	-28.09B -19.67M -17.08M -15.86M -14.63M -27.56M -1.88B -28.06M -188M -73.53M -933M -73.86M -72.24M -3.14B	-5.56B -3.89M -3.38M -3.14M -2.9M -5.45M -372M -5.55M -37.17M -14.55M -185M -14.62M -14.3M -621M
Net Debt	-25.07B -17.55M -15.24M -14.15M -13.05M -24.59M -1.68B -25.03M -168M -65.61M -832M -65.9M -64.46M -2.8B	-17.19B -12.04M -10.45M -9.71M -8.95M -16.86M -1.15B -17.17M -115M -45M -571M -45.2M -44.21M -1.92B